Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.


Public Workshop on the Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic Fatty Liver Disease (NAFLD), September 5 - 6, 2013, FDA White Oak Campus, Bldg. 31 (Rm 1503), Silver Spring, MD 20993.

Meeting information

On September 5 – 6, 2013, FDA is conducting a public workshop on Trial Designs and Endpoints for Liver Disease Secondary to Nonalcoholic fatty liver disease (NAFLD). This workshop will provide a forum to discuss trial design, including endpoints for clinical trials in NAFLD, to promote efficient drug development in this area and thus improved treatments for patients. There are no approved treatments for NAFLD and its complications of nonalcoholic steatohepatitis (NASH) and liver fibrosis and cirrhosis.

This website will be updated as meeting materials are developed.



September 5 – 6, 2013 
8:00 a.m. to 5:00 p.m. 
FDA White Oak Campus 10903 New Hampshire Ave.
Building 31, Room 1503A (Great Room)                                                                                   
Silver Spring, MD 20993 
To register for this meeting:
Registration closes on September 1, 2013.   


Meeting Materials


Page Last Updated: 04/19/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English